Eén belangrijke route die we kunnen volgen is de ontwikkeling van nieuwe geneesmiddelen.
In a forthcoming paper, the Review on Antimicrobial Resistance estimates that bringing new antimicrobials to market and improving their administration will cost about $25 billion – a significant sum, but one that pales in comparison to the costs to society if the problem is not checked.